Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

Uday R. Popat, Rohtesh S. Mehta, Roland Bassett, Julianne Chen, Benigno C. Valdez, Jitesh Kawedia, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Geath Al-Atrash, Qaiser Bashir, Stefan O. Ciurea, Chitra M. Hosing, Jin S. Im, Roy Jones, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Amanda OlsonBetul Oran, Simrit Parmar, Katayoun Rezvani, Muzaffar H. Qazilbash, Nina Shah, Samer A. Srour, Elizabeth J. Shpall, Richard E. Champlin, Borje S. Andersson

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences